A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TI, Sansom DM, Bowen MA, Minter RR, Jermutus L.
Douthwaite J, et al. Among authors: vainshtein i.
J Immunol. 2017 Jan 1;198(1):528-537. doi: 10.4049/jimmunol.1600682. Epub 2016 Nov 23.
J Immunol. 2017.
PMID: 27881707